Investigators tested the use of intravenous immune globulin (IVIg) for the treatment of adults with dermatomyositis, and a significantly higher percentage of patients experienced at least minimal improvement in disease activity in comparison with placebo in the first-ever phase 3, international, multicenter, randomized, placebo-controlled trial of the human plasma derived therapy for the condition.
Until this trial, published October 6, 2021, in The New England Journal of Medicine, there had never been an extensive evaluation of IVIg for the treatment of dermatomyositis, the study’s authors note. The study provided efficacy data for Octagam 10%, which was approved for dermatomyositis by the US Food and Drug Administration (FDA) in 2021 on the basis of this trial.
If you do not have a NEJM subscription, you may create a free account to view up to two articles per month once on the website. This will then allow review of the entire ProDERM clinical study as published.